BCRX Biocryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug RAPIVAB was approved by FDA in Dec 2014. It has also been approved in Japan, Korea and China The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
Company profile
Ticker
BCRX
Exchange
Website
CEO
Jon Stonehouse
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
SEC CIK
Corporate docs
IRS number
621413174
BCRX stock data
()
News
10 Biggest Price Target Changes For Wednesday
24 Mar 21
HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $19
24 Mar 21
The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO
23 Mar 21
BioCryst Technical Levels To Watch
22 Mar 21
Stocks That Hit 52-Week Highs On Monday
22 Mar 21
Press releases
Thinking about buying stock in Sundial Growers, RLX Technology, AMC Entertainment, BioCryst Pharmaceuticals, or GigCapital3?
22 Mar 21
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
19 Mar 21
Thinking about buying stock in Powerbridge Technologies, BioCryst Pharma, Oramed Pharma, Ampio Pharma, or Plus Therapeutics?
26 Feb 21
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
25 Feb 21
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
25 Feb 21
Calendar
1 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 272.13M | 272.13M | 272.13M | 272.13M | 272.13M | 272.13M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 17.47M | 14.56M | 14.88M | 11.43M |
Cash used (since last report) | n/a | n/a | 60.35M | 50.32M | 51.41M | 39.51M |
Cash remaining | n/a | n/a | 211.77M | 221.81M | 220.72M | 232.62M |
Runway (months of cash) | n/a | n/a | 12.1 | 15.2 | 14.8 | 20.3 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 21 | Thackray Helen M. | Common Stock | Grant | Aquire A | No | No | 0 | 100,000 | 0 | 100,000 |
31 Mar 21 | Thackray Helen M. | Emp. Stock Option Common Stock | Grant | Aquire A | No | No | 10.17 | 400,000 | 4.07M | 400,000 |
18 Mar 21 | Michael L Jones | Common Stock | Option exercise | Aquire M | No | No | 3.51 | 4,500 | 15.79K | 5,348 |
18 Mar 21 | Michael L Jones | Emp. Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.51 | 4,500 | 15.79K | 0 |
26 Feb 21 | Steve Aselage | Common Stock | Grant | Aquire A | No | No | 10.78 | 927 | 9.99K | 31,496 |
26 Feb 21 | Theresa Heggie | Common Stock | Grant | Aquire A | No | No | 10.78 | 463 | 4.99K | 13,849 |
26 Feb 21 | Nancy J Hutson | Common Stock | Grant | Aquire A | No | No | 10.78 | 463 | 4.99K | 64,756 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
68.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 177 |
Opened positions | 40 |
Closed positions | 16 |
Increased positions | 57 |
Reduced positions | 55 |
13F shares |
Current |
---|---|
Total value | 1B |
Total shares | 120.72M |
Total puts | 1.15M |
Total calls | 1.26M |
Total put/call ratio | 0.9 |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 16.26M | $121.13M |
Baker Bros. Advisors | 12.7M | $94.58M |
Vanguard | 11.6M | $86.42M |
STT State Street | 11.06M | $82.37M |
Sarissa Capital Management | 8.18M | $60.9M |
Citadel Advisors | 6.5M | $48.39M |
Deerfield Management | 5.84M | $43.48M |
Point72 Asset Management | 3.23M | $24.07M |
Oracle Investment Management | 2.98M | $22.21M |
Marshall Wace North America | 2.8M | $20.85M |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abide, absorption, adolescent, Anthony, appealing, AstraZeneca, Athyrium, attainment, behavior, biodefense, California, capped, capsule, carryforward, Cautionary, Chancery, column, contemporaneously, corroborated, covenant, cultural, culture, cybersecurity, dehydrogenase, Delinquent, discourage, doctrine, Doyle, drawn, duty, economy, EMPOWER, empty, enjoy, extinguishment, fat, fiduciary, fill, forum, France, friendly, Gayer, Germany, guarantor, hemoglobin, home, impute, imputed, inclusive, inconvenient, indefinite, Inline, inquiry, intake, Intermediate, Ireland, Isu, judicial, lactate, LDH, leaseback, Liechtenstein, linear, map, meal, monotherapy, NaN, nephrology, nonrenewal, obligor, opt, orladeyo, OrphanPacific, Overview, pattern, payoff, pharmacy, philosophy, PIK, prepaid, prepay, prescribing, purpose, pursuit, recalculated, recession, remote, reward, rewarding, risky, RPA, RPI, Scheme, shortly, situation, sized, smaller, spread, startup, stomach, truthful, unamortized, unnecessarily, unrecoverable, upcoming, voluntary, war, wellbeing, withdrew, workplace, writing
Removed:
accept, adaptive, alanine, alleviate, amending, aminotransferase, Asia, attached, attributable, Australasia, bargaining, baseline, biopharmaceutical, blinded, Canadian, Carbohydrate, caution, ceasing, Chairman, circumstance, clarified, closed, cold, collectability, collective, combination, consecutive, constitute, convey, counterparty, diarrhea, dissolve, doubt, effectuate, enactment, endpoint, entirety, exceeded, exceeding, exploratory, Ferrier, Fifty, floating, forecast, formed, fulfilling, fulfillment, gastrointestinal, half, headache, Idera, impacting, infection, inhibition, insolvency, intramuscular, leased, licensee, liquid, liquidate, liquidating, Lynne, mark, marked, materialize, MDCP, MINE, modify, moved, onset, percentage, permanently, posting, Powell, presidential, prevail, prioritized, procure, progressive, projecting, promptly, prospect, qualitative, quantitative, recovered, recur, redeemable, redeemed, redemption, remeasurement, renew, repeal, represented, restating, retention, revaluation, revalue, revise, Sakigake, season, seasonality, sequence, shareholder, spot, stoppage, studying, substitution, suffering, superior, SUPPLEMENTARY, TCJA, transient, ulodesine, unanticipated, unchanged, unfold, Unregistered, UNRESOLVED, vaccine, VAS, visual, VUW, week, Wellington, wholly, worth
Financial reports
10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
9 Aug 20
10-Q
2020 Q1
Quarterly report
10 May 20
10-K
2019 FY
Annual report
13 Mar 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
14 Mar 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
Current reports
8-K
Regulation FD Disclosure
26 Mar 21
8-K
Regulation FD Disclosure
22 Mar 21
8-K
Regulation FD Disclosure
18 Mar 21
8-K
Regulation FD Disclosure
2 Mar 21
8-K
Regulation FD Disclosure
25 Feb 21
8-K
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
25 Feb 21
8-K
Regulation FD Disclosure
3 Feb 21
8-K
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
22 Jan 21
8-K
Regulation FD Disclosure
22 Dec 20
8-K
BioCryst Provides Update on Galidesivir Program
22 Dec 20
Registration and prospectus
S-3ASR
Automatic shelf registration
1 Mar 21
S-8
Registration of securities for employees
12 Aug 20
S-8
Registration of securities for employees
10 Jun 20
S-8
Registration of securities for employees
10 Jun 20
S-8
Registration of securities for employees
10 Jun 20
424B2
Prospectus for primary offering
29 May 20
424B5
Prospectus supplement for primary offering
27 May 20
S-3
Shelf registration
24 Apr 20
424B5
Prospectus supplement for primary offering
21 Nov 19
424B2
Prospectus for primary offering
14 Nov 19
Proxies
DEFA14A
Additional proxy soliciting materials
13 Apr 21
DEF 14A
Definitive proxy
13 Apr 21
DEFA14A
Additional proxy soliciting materials
31 Mar 20
DEF 14A
Definitive proxy
31 Mar 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
17 Apr 19
DEF 14A
Definitive proxy
17 Apr 19
DEF 14A
Definitive proxy
28 Sep 18
PRE 14A
Preliminary proxy
17 Sep 18
DEFM14A
Proxy related to merger
30 May 18
Other
EFFECT
Notice of effectiveness
15 May 20
CORRESP
Correspondence with SEC
11 May 20
CORRESP
Correspondence with SEC
3 May 20
CT ORDER
Confidential treatment order
1 May 20
UPLOAD
Letter from SEC
26 Apr 20
CT ORDER
Confidential treatment order
17 Dec 18
CT ORDER
Confidential treatment order
6 Jun 18
CT ORDER
Confidential treatment order
5 Apr 18
EFFECT
Notice of effectiveness
11 Dec 17
CORRESP
Correspondence with SEC
7 Dec 17
Ownership
SC 13G/A
BIOCRYST PHARMACEUTICALS / STATE STREET ownership change
12 Apr 21
4
BIOCRYST PHARMACEUTICALS / Helen M. Thackray ownership change
2 Apr 21
4
BIOCRYST PHARMACEUTICALS / Michael L Jones ownership change
22 Mar 21
4
BIOCRYST PHARMACEUTICALS / ROBERT ALEXANDER INGRAM ownership change
2 Mar 21
4
BIOCRYST PHARMACEUTICALS / Nancy J Hutson ownership change
2 Mar 21
4
BIOCRYST PHARMACEUTICALS / THERESA HEGGIE ownership change
2 Mar 21
4
BIOCRYST PHARMACEUTICALS / STEVE ASELAGE ownership change
2 Mar 21
4
BIOCRYST PHARMACEUTICALS / William P Sheridan ownership change
24 Feb 21
4
BIOCRYST PHARMACEUTICALS / Yarlagadda S Babu ownership change
23 Feb 21
SC 13G/A
BIOCRYST PHARMACEUTICALS / Point72 Asset Management ownership change
16 Feb 21
Patents
APP
Utility
Human Plasma Kallikrein Inhibitors
18 Mar 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
GRANT
Utility
Methods and compositions for treatment of Zika virus infection
2 Mar 21
Inventors: Yarlagadda S. Babu, Pravin L. Kotian, Shanta Bantia
APP
Utility
Human Plasma Kallikrein Inhibitors
18 Feb 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
APP
Utility
Human Plasma Kallikrein Inhibitors
18 Feb 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
GRANT
Utility
Compositions and uses of amidine derivatives
2 Feb 21
Inventors: Yarlagadda S Babu, Vivekanand P Kamath, Walter Gowan
Transcripts
2020 Q4
Earnings call transcript
25 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
5 Mar 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
6 Aug 19
2019 Q1
Earnings call transcript
8 May 19
2018 Q4
Earnings call transcript
4 Mar 19
2018 Q3
Earnings call transcript
6 Nov 18
Reddit threads
$ATOS - Currently trading 45% under recent Direct Offering from $2.88 to $1.75
13 Apr 21
Have you ever lost so much money on a particular stock that you just refused to sell it out of principle?
12 Apr 21
30 min ago $GLSI released the results from their phase 2 trials - 0 Breast Cancer reoccurences and immediate phase 3 push
9 Apr 21
If you had $10000 what would you spend it on?
9 Apr 21
What stocks are actually well priced or even undervalued right now or is the answer nothing?
8 Apr 21
With the market at an all time high, what are some less risky investment options that make more sense?
7 Apr 21
What are your highest conviction picks
6 Apr 21
Long term stocks
4 Apr 21
$BCRX Big Pharma Assassin BCX9930 to Jump from Phase 1 to Phase 3 Pivotal Trials in PNH
4 Apr 21
Rolling Puts Backwards?
3 Apr 21